Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
09/2003
09/25/2003US20030181435 Systemic lupus erythematosus therapy
09/25/2003US20030181432 Particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy
09/25/2003US20030181430 Novel topical oestroprogestational compositions with a systemic effect
09/25/2003US20030181421 Method of administering bisphosphonates
09/25/2003US20030181415 Use of these compounds for prevention and inhibition of malignant epithelial lesions associated with papilloma virus, such as cervical cancer
09/25/2003US20030181414 Multiparticulate enteric coated and multiparticulate enteric coated prolonged release formulations containing NADH
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181410 Methods for encapsulating plasmids in lipid bilayers
09/25/2003US20030181398 Injecting penicillins, cephalosporins, tetracyclines, erythromycins, tylosins, quinolone and other antibiotics, to skins of animals such as cattle, swine or sheep, for prophylaxis of respiratory system disorders
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181387 Intranasal administration of polypeptides in powdered form
09/25/2003US20030181371 Compositions and methods of using collajolie
09/25/2003US20030181367 Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.
09/25/2003US20030181362 Receptor
09/25/2003US20030181356 Treating emphysema by reducing the amount of force the fibers in the lung (e.g., the collagen and elastin fibers in the walls of the alveoli) must bear. The invention features a pharmaceutically acceptable composition comprising lipid for
09/25/2003US20030180950 Reversible masking of liposomal complexes for targeted delivery
09/25/2003US20030180755 Pharmaceutical compositions in particulate form
09/25/2003US20030180493 Auxiallary implement for patch application
09/25/2003US20030180485 Method of manufacturing seamless capsule
09/25/2003US20030180414 Method of controlling release of bitterness inhibitors in chewing gum and gum produced thereby
09/25/2003US20030180389 Effervescent glucosamine, chondroitin and MSM formula
09/25/2003US20030180386 Aqueous metal bicarbonate solution and method of use
09/25/2003US20030180382 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
09/25/2003US20030180380 Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use
09/25/2003US20030180379 Microbiocides; anticancer agents; bactericides; antiinflammatory agents; fungicides; viricides
09/25/2003US20030180378 Dry powders of metal-containing compounds
09/25/2003US20030180371 Purity aqueous solution of amylopectin; controlling pH
09/25/2003US20030180370 Iron oxide core with overcoating shell; antitumor agents
09/25/2003US20030180369 Microcapsule powder
09/25/2003US20030180368 Mixing with emulsifiers in liquid containing polymer; agitating with nonsolvent
09/25/2003US20030180367 Microparticles of water-insoluble substances
09/25/2003US20030180366 Bioadhesive drug delivery system
09/25/2003US20030180365 Preparation containing an oxygen carrier for regeneration of the skin in the case of oxygen deficiency
09/25/2003US20030180364 Catheter injectable depot compositions and uses thereof
09/25/2003US20030180363 Biodegradation polymer; liquid phase polyoxyethylene glycol
09/25/2003US20030180362 Multi-stage oral drug controlled-release system
09/25/2003US20030180361 Opioids; analgesics; solid dosage form; sustained release
09/25/2003US20030180360 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
09/25/2003US20030180359 Controlled release
09/25/2003US20030180358 Controlled release
09/25/2003US20030180357 Core with coating; water soluble dye in matrix as core; gellan gum coatings; easier detection of tablet
09/25/2003US20030180356 Hormone replacement therapy; compressed blend
09/25/2003US20030180354 Amlodipine maleate formulations
09/25/2003US20030180353 Mixture of levothyroxine sodium and liothyronine sodium
09/25/2003US20030180352 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
09/25/2003US20030180350 Combination compositions
09/25/2003US20030180349 Administering before or after onset of disease
09/25/2003US20030180348 Transcellular drug delivery system
09/25/2003US20030180347 Polymer matrix; support backings; adhesive; active material
09/25/2003US20030180335 Moisturizers; transdermal absorption; ethylene oxide-propylene oxide adduct
09/25/2003US20030180332 Novel pharmaceutical composition
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180283 Method and apparatus for producing dry particles
09/25/2003US20030180281 Preparations for topical skin use and treatment
09/25/2003US20030180260 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
09/25/2003US20030180246 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
09/25/2003US20030180244 Use of oligomers and polymers for drug solublization, stabilization, and delivery
09/25/2003US20030180235 Matrix for preparing microparticles or nanoparticles, method for making said particles and resulting particles
09/25/2003US20030180228 Aerosol container for formulations of salmeterol xinafoate
09/25/2003US20030180227 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
09/25/2003US20030180220 Liposomes containing hydrophobic iodo compound
09/25/2003US20030178044 Micromesh interproximal devices
09/25/2003US20030178022 Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
09/25/2003US20030177941 For ink jet imaging/anticounterfeiting; semiconductors
09/25/2003US20030177868 Cross-linked polymerlic nanoparticles and metal nanoparticles derived therefrom
09/25/2003DE20301468U1 Pain-alleviating chewable mass, especially for application to teeth to combat toothache and other caries symptoms, containing analgesic, disinfecting, antiinflammatory and infection inhibiting active agents
09/25/2003CA2748620A1 Naltrexone hydrochloride compositions
09/25/2003CA2518794A1 Compositions and methods for treating emphysema
09/25/2003CA2479315A1 Improvements in vaccination
09/25/2003CA2479295A1 Progesterone oral drug delivery system
09/25/2003CA2479212A1 Central airway administration for systemic delivery of therapeutics
09/25/2003CA2478867A1 Formulations of anthraquinone derivatives
09/25/2003CA2478766A1 Polymer composition loaded with cells
09/25/2003CA2478758A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
09/25/2003CA2478500A1 Crystalline parecoxib sodium
09/25/2003CA2478336A1 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
09/25/2003CA2478248A1 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003CA2478206A1 Sulfatase inhibiting continuous progestogen contraceptive regimens
09/25/2003CA2478194A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
09/25/2003CA2478165A1 Sulfatase inhibiting progestogen-only contraceptive regimens
09/25/2003CA2478074A1 Percutaneous absorption promoters and compositions for treating athlete's foot
09/25/2003CA2477592A1 Powdery medicinal compositions for inhalation and process for producing the same
09/25/2003CA2476908A1 Composition comprising an l-ascorbic acid and an organic base for treatment of ocular disorders
09/25/2003CA2476777A1 Absorbent hydrogels
09/24/2003EP1346737A1 Infusion pump with access regulator
09/24/2003EP1346727A2 Method for obtaining antigenic aggregates and the use thereof in formulations
09/24/2003EP1346723A1 Multiparticulate enteric coated and multiparticulate enteric coated prolonged release formulations containing NADH
09/24/2003EP1346722A1 Method for producing preparation containing bioactive substance
09/24/2003EP1346721A1 W/o/w composite emulsion
09/24/2003EP1346649A2 Water dispersible compositions containing natural hydrophobic pigment, method of preparing same and their use
09/24/2003EP1345979A2 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters
09/24/2003EP1345968A2 Crystals of whole antibodies and fragments thereof and methods for making and using them
09/24/2003EP1345901A2 Process for making amlodipine, derivatives thereof, and precursors therefor
09/24/2003EP1345893A2 Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells
09/24/2003EP1345683A1 Encapsulation of emulsions
09/24/2003EP1345682A2 Preparation of microparticles having improved flowability
09/24/2003EP1345630A1 Stabilised radiopharmaceutical compositions
09/24/2003EP1345629A2 Particles for inhalation having sustained release properties
09/24/2003EP1345626A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
1 ... 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 ... 2991